Background : Mild cognitive impairment (MCI) is an intermediate phase between normal aging and dementia. Since a majority of amnestic MCI (aMCI) cases progress to Alzheimer’s disease (AD), it is considered the prodromal stage of AD and therefore, a treatment target for the prevention of further cogn...
Background : Mild cognitive impairment (MCI) is an intermediate phase between normal aging and dementia. Since a majority of amnestic MCI (aMCI) cases progress to Alzheimer’s disease (AD), it is considered the prodromal stage of AD and therefore, a treatment target for the prevention of further cognitive decline. However, no medications have been shown to have symptomatic or preventive benefits in patients with MCI.
Objectives : The aim of this study is to explore the effectiveness and safety of Kami Guibi-tang (KGT) in aMCI patients, which is a herbal medicine used in Korean medicine to treat amnesia, insomnia, loss of appetite, and depression.
Methods : This study was designed as a single-center, randomized, double-blind, placebo-controlled pilot study. Participants diagnosed with aMCI were randomized to receive either KGT or placebo granules for 24 weeks. The efficacy measures were changes in Seoul Neuropsychological Screening Battery (SNSB) scores. The safety assessments included adverse events and abnormalities in vital sign, blood chemistry, electrocardiogram(ECG) and Brain MRI.
Results : 16 patients in KGT group and 14 patients in placebo group completed the study. The mean CDR-Sum of boxes(SB) was significantly improved in KGT group compared to placebo group. The mean total SNSB scores, and the scores of SVLT recall, Rey recall, Rey recognition tests in memory domain increased significantly within the KGT group compared to baseline, but not in the placebo group. The occurrence of adverse events was not significantly different between the two groups, and there were no abnormalities in vital sign, blood test, ECG or Brain MRI after the intervention.
Conclusions : KGT may be a potential treatment option for improving cognitive function in aMCI patients.
Background : Mild cognitive impairment (MCI) is an intermediate phase between normal aging and dementia. Since a majority of amnestic MCI (aMCI) cases progress to Alzheimer’s disease (AD), it is considered the prodromal stage of AD and therefore, a treatment target for the prevention of further cognitive decline. However, no medications have been shown to have symptomatic or preventive benefits in patients with MCI.
Objectives : The aim of this study is to explore the effectiveness and safety of Kami Guibi-tang (KGT) in aMCI patients, which is a herbal medicine used in Korean medicine to treat amnesia, insomnia, loss of appetite, and depression.
Methods : This study was designed as a single-center, randomized, double-blind, placebo-controlled pilot study. Participants diagnosed with aMCI were randomized to receive either KGT or placebo granules for 24 weeks. The efficacy measures were changes in Seoul Neuropsychological Screening Battery (SNSB) scores. The safety assessments included adverse events and abnormalities in vital sign, blood chemistry, electrocardiogram(ECG) and Brain MRI.
Results : 16 patients in KGT group and 14 patients in placebo group completed the study. The mean CDR-Sum of boxes(SB) was significantly improved in KGT group compared to placebo group. The mean total SNSB scores, and the scores of SVLT recall, Rey recall, Rey recognition tests in memory domain increased significantly within the KGT group compared to baseline, but not in the placebo group. The occurrence of adverse events was not significantly different between the two groups, and there were no abnormalities in vital sign, blood test, ECG or Brain MRI after the intervention.
Conclusions : KGT may be a potential treatment option for improving cognitive function in aMCI patients.
주제어
#"경도인지장애", "기억상실형 경도인지장애", "인지기능", "한약", "가미귀비탕", "서울신경심리검사", "Mild Cognitive Impairment", "Amnestic Mild Cognitive Impairment", "Cognitive function", "Herbal medicine", "Kami Guibi-tang(KGT)", "Seoul Neuropsychological Screening
※ AI-Helper는 부적절한 답변을 할 수 있습니다.